Merrimack Pharma (MACK) Reports Q4 Loss of $0.89

Note: EPS may not be comparable

Merrimack Pharma (NASDAQ: MACK) reported Q4 EPS of ($0.89), versus ($0.28) reported last year. Revenue for the quarter came in at $0 versus the consensus estimate of $11 million.

• Net loss attributable to Merrimack's continuing operations for the three months ended December 31, 2017 was $11.8 million, or $0.89 per share, compared to a net loss attributable to Merrimack\'s continuing operations of $40.1 million, or $2.93 per share, for the three months ended December 31, 2016.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Is the global equity rally broadening? UBS weighs in